Aigen Investment Management LP Raises Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Aigen Investment Management LP raised its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 84.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,037 shares of the company’s stock after buying an additional 4,125 shares during the period. Aigen Investment Management LP’s holdings in Twist Bioscience were worth $408,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Signaturefd LLC boosted its holdings in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC bought a new position in Twist Bioscience during the 2nd quarter valued at approximately $43,000. Blue Trust Inc. lifted its holdings in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after buying an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in Twist Bioscience in the 2nd quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after buying an additional 381 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on TWST shares. Barclays dropped their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Evercore ISI lifted their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners boosted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Robert W. Baird raised their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. upped their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $51.22.

Insider Activity at Twist Bioscience

In other news, insider Dennis Cho sold 3,104 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $134,123.84. Following the sale, the insider now owns 75,289 shares in the company, valued at $3,253,237.69. This represents a 3.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Paula Green sold 3,310 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $143,025.10. Following the sale, the senior vice president now directly owns 84,585 shares of the company’s stock, valued at $3,654,917.85. This trade represents a 3.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 98,118 shares of company stock valued at $4,391,151 in the last 90 days. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Stock Performance

TWST stock opened at $38.96 on Friday. The firm has a 50 day moving average price of $43.90 and a 200-day moving average price of $45.88. Twist Bioscience Co. has a 52-week low of $18.80 and a 52-week high of $60.90. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -10.20 and a beta of 1.78.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.